A Phase 1 interventional study of AZD1152 in Solid Tumors, sponsored by AstraZeneca. Terminated at 2 sites in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2009-06-22.
Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment
The primary purpose of this protocol is to investigate the safety and tolerability of AZD1152 when given as a continuous 2-hour infusion every week and every 2 weeks in patients with advanced solid malignancies.
9,365 studies on the registry are indexed under Neoplasms; 2,489 are open to participants now.
This study's planned enrollment of 70 is above the median of 50 across 7,253 interventional studies indexed under Neoplasms.
Browse Neoplasms studies →AstraZeneca is the lead sponsor of 3,429 studies on the registry; 270 are open to participants now.
Of its 357 completed or terminated interventional studies of FDA-regulated products, 173 (48%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
2-hour continuous intravenous infusion
Safety and Tolerability
Time frame: Assessed at each visit
Pharmacokinetics
Time frame: Assessed at predetermined timepoints after dose administration
Effect on biomarkers
Time frame: Assessed after treatment
Anti-tumor activity
Time frame: Assessed after treatment
This study is terminated, as verified in Jun 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
AstraZeneca